Session » Muscle Biology, Myositis and Myopathies - Poster II: Clinical

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2325

ANTI-Hmgcr Antibodies Demonstrate High Diagnostic VALUE in the Diagnosis of Immune Mediated Necrotizing Myopathy Following Statin Exposure

9:00AM-11:00AM: Abstract Number: 2314

Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy

9:00AM-11:00AM: Abstract Number: 2312

Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2327

Cardiac Involvement in Inflammatory Myopathies: A Report from the Remicam Registry

9:00AM-11:00AM: Abstract Number: 2321

Early Damage and Mortality in a Cohort of Patients with Myositis Followed up to 20 Years

9:00AM-11:00AM: Abstract Number: 2324

Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis

9:00AM-11:00AM: Abstract Number: 2323

Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2309

Focal Myositis: New Insights on Diagnosis and Pathology

9:00AM-11:00AM: Abstract Number: 2319

High Prevalence of Asymptomatic Vertebral Fractures in Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 2307

Influence of Season and Residential Environment on Development of Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2311

Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2326

Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2329

Intravenous Immunoglobulins in the Treatment of Idiophatic Inflammatory Myopathies: Where Do We Stand?

9:00AM-11:00AM: Abstract Number: 2320

Oropharyngeal Dysphagia in Autoimmune Myositis

9:00AM-11:00AM: Abstract Number: 2317

Preliminary Validation of a Magnetic Resonance Imaging-Based Inflammatory Scoring System in Adult Myositis

9:00AM-11:00AM: Abstract Number: 2313

Profile of Cardiovascular Burden in Myositis: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 2318

Real World Use of the Myositis Autoantibody Panel

9:00AM-11:00AM: Abstract Number: 2328

Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2316

Successful Treatment of Statin-Induced Autoimmune Myopathy without Corticosteroids

9:00AM-11:00AM: Abstract Number: 2322

The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle

9:00AM-11:00AM: Abstract Number: 2315

The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2310

The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2308

Thigh Muscle MRI Reveals Extensive Muscle Edema and Early Fatty Replacement in Patients with Immune-Mediated Necrotizing Myopathy

9:00AM-11:00AM: Abstract Number: 2330

Ultrasound Imaging in Inclusion Body Myositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].